RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
5 Articles
5 Articles
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Poor memory function has been noted in individuals that developed Alzheimer's disease up to 15 years before the eventual diagnosis of the condition. Experiments in a mouse model for the disease have now tracked down a possible cause for this early symptom: the extracellular accumulation of a soluble amyloid-β peptide assembly, dubbed Aβ*. When Aβ* is isolated from these mice and injected into rats, the rats also experience temporary memory deter…
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers Disease
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer’s disease Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” […]
#Promising Long-Term Efficacy of Blarcamesine in Early Alzheimers Disease Insights from the Phase IIb/III Open-Label ...
Alzheimer's disease (AD), characterized by cognitive decline and neurodegeneration, poses a significant burden on individuals, families, and healthcare systems worldwide. The search for effective treatments has gained momentum, particularly focusing on early intervention strategies. In this context, recent announcements from Anavex Life Sciences have shed light on the promising long-term efficacy of blarcamesine, a novel therapeutic candidate, i…
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage